Use of ranolazine for elevated brain-type natriuretic peptide

Details Use of ranolazine for elevated brain-type natriuretic peptide Use of ranolazine for elevated brain-type natriuretic peptide

A - Human Necessities

61

K

A61K 31/495 (2006.01) A61P 9/10 (2006.01) G01N 33/68 (2006.01)

Patent

CA 2689633

This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an oral dose.

La présente invention concerne l'utilisation de la ranolazine pour réduire le risque d'événements coronariens néfastes chez un patient mammifère. De manière caractéristique, le peptide natriurétique est associé à la maladie coronarienne, le syndrome coronarien aigu, et/ou le dysfonctionnement diastolique. La ranolazine peut être administrée au patient sous forme d'une solution intraveineuse ou de dose orale.

Affiliated with

Also associated with

Rating

Use of ranolazine for elevated brain-type natriuretic peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of ranolazine for elevated brain-type natriuretic peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ranolazine for elevated brain-type natriuretic peptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1452580